# A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer

> **NCT03641976** · PHASE2 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 120 (estimated)

## Conditions studied

- Unresectable Metastatic Right-sided Colon Cancer Starting First-line Combination Chemotherapy
- Unresectable Metastatic Right-sided Colon Cancer, Stage IV

## Interventions

- **DRUG:** A-FOLFOXIRI
- **DRUG:** Arm II (A-FOLFOX/A-FOLFIRI)

## Key facts

- **NCT ID:** NCT03641976
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-03
- **Primary completion:** 2024-06
- **Final completion:** 2024-06
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03641976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03641976, "A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03641976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*